These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 30773020)

  • 1. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
    Kidokoro K; Cherney DZI; Bozovic A; Nagasu H; Satoh M; Kanda E; Sasaki T; Kashihara N
    Circulation; 2019 Jul; 140(4):303-315. PubMed ID: 30773020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK/Ta-Ins2
    Fujita H; Otomo H; Takahashi Y; Yamada Y
    Biochem Biophys Res Commun; 2022 Dec; 635():84-91. PubMed ID: 36265286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockout of Na
    Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
    Cherney DZ; Perkins BA; Soleymanlou N; Maione M; Lai V; Lee A; Fagan NM; Woerle HJ; Johansen OE; Broedl UC; von Eynatten M
    Circulation; 2014 Feb; 129(5):587-97. PubMed ID: 24334175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
    Takakura S; Takasu T
    Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project).
    Nielsen SF; Duus CL; Buus NH; Bech JN; Mose FH
    JMIR Res Protoc; 2024 May; 13():e56067. PubMed ID: 38680116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.
    Lee YH; Kim SH; Kang JM; Heo JH; Kim DJ; Park SH; Sung M; Kim J; Oh J; Yang DH; Lee SH; Lee SY
    Am J Physiol Renal Physiol; 2019 Oct; 317(4):F767-F780. PubMed ID: 31390268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury.
    Faulhaber-Walter R; Chen L; Oppermann M; Kim SM; Huang Y; Hiramatsu N; Mizel D; Kajiyama H; Zerfas P; Briggs JP; Kopp JB; Schnermann J
    J Am Soc Nephrol; 2008 Apr; 19(4):722-30. PubMed ID: 18256360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the macula densa sodium glucose cotransporter type 1-neuronal nitric oxide synthase-tubuloglomerular feedback pathway in diabetic hyperfiltration.
    Zhang J; Cai J; Cui Y; Jiang S; Wei J; Kim YC; Chan J; Thalakola A; Le T; Xu L; Wang L; Jiang K; Wang X; Wang H; Cheng F; Buggs J; Koepsell H; Vallon V; Liu R
    Kidney Int; 2022 Mar; 101(3):541-550. PubMed ID: 34843754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
    Locatelli M; Zoja C; Conti S; Cerullo D; Corna D; Rottoli D; Zanchi C; Tomasoni S; Remuzzi G; Benigni A
    J Pathol; 2022 Apr; 256(4):468-479. PubMed ID: 35000230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOD1, but not SOD3, deficiency accelerates diabetic renal injury in C57BL/6-Ins2(Akita) diabetic mice.
    Fujita H; Fujishima H; Takahashi K; Sato T; Shimizu T; Morii T; Shimizu T; Shirasawa T; Qi Z; Breyer MD; Harris RC; Yamada Y; Takahashi T
    Metabolism; 2012 Dec; 61(12):1714-24. PubMed ID: 22632894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
    Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
    Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats.
    Gal A; Burton SE; Weidgraaf K; Singh P; Lopez-Villalobos N; Jacob A; Malabu U; Burchell R
    Domest Anim Endocrinol; 2020 Jan; 70():106376. PubMed ID: 31585313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium-glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin-overloaded streptozotocin-induced diabetic mice.
    Shimada K; Kanasaki K; Kato M; Ogura Y; Takagaki Y; Monno I; Hirai T; Kitada M; Koya D
    J Diabetes Investig; 2022 Jun; 13(6):955-964. PubMed ID: 35098679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.